Xeris Biopharma reports revenue surge as Trane Technologies sees institutional shifts

Xeris Biopharma reported an 81% year-over-year increase in Recorlev revenue for the second quarter of 2026, reaching approximately $56.8 million. The company attributed this growth to increased patient demand for the endogenous Cushing’s syndrome treatment. Additionally, Xeris received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent for Keveyis, which is expected to extend intellectual property protection through at least 2039.

Trane Technologies plc saw mixed institutional activity in the second quarter. Hennion & Walsh Asset Management Inc. reduced its stake in the company by 16.8%, while other firms like Trust Point Inc. and Valeo Financial Advisors LLC increased their holdings. Trane Technologies maintains a market capitalization of $106.10 billion.